Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 10 months ago

Anticoagulation
ACC 25: Optimizing DAPT Duration
Author(s): Hyo-Soo Kim Added: 1 month ago
ACC 25 - Findings from a stratified study investigating coronary stenting and bleeding risk suggest 3 months are the optimal duration of DAPT after PCI.Dr Hyo-Soo Kim (Seoul National University Hospital, KR) sits down to discuss the first randomized study stratifying patients receiving percutaneous coronary intervention with drug eluting stents according to bleeding risk based on the ARC HBR… View more

Anticoagulation

Intervention
EuroPCR 25: The DANAMI-3-DEFER Trial
Author(s): Jacob Thomsen Lønborg Added: 2 days ago
EuroPCR 25 - 10-year follow-up findings of DANAMI-3-DEFER show a deferred stenting strategy may reduce HF hospitalisation in ST-elevation myocardial infarction (STEMI) patients.We are joined by Dr Jacob Lønborg (Rigshospitalet, Copenhagen, DK) to discuss key findings from the 10-year follow-up of the DANAMI-3-DEFER (NCT01435408) trial. This randomized controlled trial compared deferred stent… View more

Intervention

MI/ACS
Consequences and Management of Excessive Ostial Stent Protrusion
Author(s): Arditya Damarkusuma Added: 1 year ago
In this video, Dr Arditya Damarkusuma (Universitas Gadjah Mada, ID) presents his case report on aorto-ostial lesions, recently published in ICR Journal.This case covers the restenosis of a markedly protruding stent at the right coronary ostium in a 54-year old man, and is unusual in its 10-year longevity. Intravascular ultrasound-guided in-stent restenosis intervention using a wire bumper… View more

Imaging & Diagnostics

Intervention
PERFORMANCE II: Two-Year Outcomes
Author(s): William Gray Added: 3 weeks ago
Safety and effectiveness outcomes of a 3-in-1 carotid stent delivery system show no major strokes at 30-day and one-year follow ups and significantly low rates of clinically driven target lesion revascularisation at two years.Dr William Gray (Main Line Health, Pennsylvania, US) joins us to discuss the first European presentation of the two-year outcomes from PERFORMANCE II (NCT04201132; Contego… View more

Vascular Disease and Surgery
ACC 25: The SMART-CHOICE 3 Trial
Author(s): Joo-Yong Hahn Added: 1 month ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more

Anticoagulation

Intervention
The XLIMIT Trial: XLIMUS® DES Shows Non-Inferiority to Synergy™ DES
Author(s): Luca Testa Added: 11 months ago
Dr Luca Testa (IRCCS Policlinico San Donato, IT) discusses the results of the XLIMIT Trial at the EuroPCR 2024 congress in Paris, France.In this video interview, Dr Testa explains the technology behind the XLIMUS® drug-eluting stent (Cardionovum®) and its benefits. He also reviews the XLIMIT Trial, detailing the study design, selection criteria and clinical outcomes.Specifically, the 6 to 9… View more

Intervention
Job title: Head, Product Development Team, Drug-eluting Stents
TCT 23: AGENT IDE
Author(s): Robert Yeh Added: 1 year ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more

Intervention
The Hybrid Approach in CAD with Restore® DEB
Author(s): Alfonso Ielasi Added: 11 months ago
In this comprehensive video series, Dr Alfonso Ielasi (IRCCS Ospedale Galeazzi Sant'Ambrogio, IT) delves into the approach of using Restore® Drug-Eluting Balloon (DEB) in treating Coronary Artery Disease (CAD). View more

Intervention